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Acute Seizures Occurring in
Association With SARS-CoV-2
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Claudia Kirsch, Ruben Kuzniecky and Souhel Najjar
Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, North Shore University Hospital, Manhasset, NY,
United States

Seizures are an infrequent and serious neurological complication of SARS-CoV-2
infection, with limited data describing the etiology and the clinical context in which these
occur or the associated electrographic and imaging findings. This series details four
cases of seizures occurring in patients with COVID-19 with distinct time points, underlying
pathology, and proposed physiological mechanisms. An enhanced understanding of
seizure manifestations in COVID-19 and their clinical course may allow for earlier
detection and improved patient management.
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INTRODUCTION
Coronavirus disease 2019 (COVID-19) associated with severe respiratory syndrome coronavirus
2 (SARS-CoV-2) presents with cough, fever, fatigue, and gastrointestinal symptoms. However,
neurologic manifestations are reported in a third of patients and include dizziness, headaches,
impaired consciousness, neuromuscular injury, changes in taste or smell, stroke, ataxia, or
seizures (1).
Two early multicenter studies from China reported seizures in 0.47–0.66% of patients with
COVID-19 (1, 2). Subsequent individual cases of seizures associated with COVID-19 were
described, both as a presenting feature of COVID-19 and as a complication emerging later in the
course of critically ill patients (3–12). Although seizures are uncommon, their occurrence is not
unexpected given their association with other human coronavirus infections such as SARS-CoV
and MERS reported in the literature (13, 14). There is increasing appreciation of the SARS-CoV-2
pathogenic mechanisms causing neurological injury and seizures.
This paper presents the clinical course and electroencephalographic (EEG) and
neuroradiographic features of four cases of acute symptomatic seizure in the setting of SARSCOV-2 infection, highlighting distinct pathological mechanisms by which seizures may occur in
the context of the unique and formidable illness of COVID-19.

CASE PRESENTATIONS
Case 1
A 48-year-old woman presented to urgent care complaining of fever, cough, vomiting, and
malaise. Pneumonia was confirmed on chest X-ray, and she was prescribed with doxycycline
and azithromycin. Three days later, she was brought in emergently for progressive confusion.
She was febrile and tachypneic, with a blood pressure of 179/87 mmHg. She was alert, though
aphasic, with impaired verbal output, naming, comprehension, and repetition. Babinski reflex was
positive bilaterally.
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Case 2

The patient then experienced three consecutive generalized
tonic–clonic seizures (GTCS) associated with full body stiffening,
dilated pupils, foaming at the mouth, and tongue bite up to
6 min apart, concerning for status epilepticus for which she
was administered intravenous (IV) lorazepam and levetiracetam
with resolution.
Initial laboratories were notable for mild transaminitis (AST
34 µ/L, ALT 53 µ/L) and elevated inflammatory markers (Ddimer 279 ng/ml, ferritin 357 ng/ml, and C-reactive protein 32
mg/ml). The toxicology result was negative. The chest X-ray
result revealed bilateral interstitial infiltrates, and non-contrast
computed tomography (CT) of the head was unrevealing.
The patient was empirically treated for encephalitis with
acyclovir and ceftriaxone. Lumbar puncture was traumatic,
with the white blood cell count corrected to five per cubic
millimeter and elevated protein of 125 mg/dl. The results of
cerebrospinal fluid (CSF) gram stain, culture, and polymerase
chain reaction (PCR) for herpes were subsequently negative.
The nasopharyngeal COVID-19 PCR test result was positive.
CSF COVID-19 PCR was unavailable. Continuous EEG was
performed postictally, showing severe generalized slowing but no
epileptiform activity.
The patient remained febrile, tachycardic, and tachypneic,
requiring intubation for hypoxemic respiratory failure. A 5day course of high-dose IV methylprednisolone was given for
suspected COVID-19-associated central nervous system (CNS)
involvement, as well hydroxychloroquine and a single 400-mg
dose of tocilizumab. On day 13, the patient was extubated,
with significant neurological improvement and resolution of
her aphasia. MRI of the brain on day 19 demonstrated T2weighted (T2) and fluid-attenuated inversion recovery (FLAIR)
hyperintensity in the medial temporal lobes bilaterally without
restricted diffusion (Figure 1). The patient gradually improved
and was discharged on day 25.

A 29-year-old woman with iron deficiency anemia and
menorrhagia presented after two GTCS with postictal confusion
in the context of preceding fever, cough, and headache for 2
weeks. The initial vital signs were normal, except for tachycardia.
While under observation, she suffered another GTCS with right
gaze deviation, forced eye opening, tonic limb movements, and
loss of awareness. This was aborted with IV lorazepam and
levetiracetam. Postictal right-sided paralysis was noted.
The nasopharyngeal COVID-19 PCR test result was positive.
Prolactin and D-dimer were notably elevated. Non-contrast
CT of the head revealed edema, mass effect, and subcortical
hemorrhages in the left temporal and parietal lobes as well as
a hyperdense left transverse sigmoid sinus (Figure 1). A CT
venogram confirmed left sigmoid and transverse cortical venous
thrombosis (CVT), for which IV heparin was commenced.
Pulmonary ground-glass opacities were noted on imaging.
EEG demonstrated asynchronous slowing and attenuation
over the left hemisphere. CT of the head on day 2 showed
evolving left temporal–parietal hemorrhagic infarction with
midline shift and partial effacement of the right lateral and
third ventricles. The patient developed bilateral abducens palsies
and papilledema and was given acetazolamide for increased
intracranial pressure. Mentation improved significantly by day
9 as she was able to respond to questions and moved all limbs
antigravity, with a mild right facial droop. Hypercoagulable
workup revealed anticardiolipin IgM antibodies. The patient was
discharged on enoxaparin and levetiracetam.

Case 3
A 64-year-old woman with a history of hypertension, stage
4 chronic kidney disease, and non-insulin-dependent type 2
diabetes presented after two GTCS, lasting 2 min each, with
postictal unresponsiveness. There had been 3 days of preceding

FIGURE 1 | (A) Case 1: 48-year-old, COVID-19-positive female with altered mental status; 3-T MRI axial FLAIR image (red arrows) of hyperintense FLAIR in the medial
temporal lobe because of altered mental status and seizures, unable to hold still for scan, with resultant motion artifact. (B–D) Case 2: 29-year-old, COVID-19-positive
female who presented with seizures. (B) 1.5-T MRI axial FLAIR (red arrow) of the left temporal lobe with hemorrhagic venous infarction, with the FLAIR hyperintensity
consistent with edema and mass effect effacing the left ambient cistern. (C) 1.5-T MRI—time-of-flight MRI—with red arrows noting the absent flow void with venous
thrombosis of the left transverse and sigmoid sinus and the left internal jugular vein. (D) CT venogram with the purple arrow demonstrating absent contrast
enhancement and thrombosis of the left transverse and sigmoid sinus.
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FIGURE 2 | (A–F) Case 3: 64-year-old COVID-positive female, axial 3-T MRI. (A–C) Axial FLAIR. (D,E) Axial DWI. (F) Axial apparent diffusion coefficient (ADC). FLAIR
hyperintensity in the left was greater than that in the right cerebral hemispheres, with punctate DWI hyperintensity (red arrowheads) with ADC restricted diffusion. (F)
Left precentral sulcus and right superior medial right parietal lobe, foci of FLAIR, DWI hyperintensity without restricted diffusion, and ADC T2-shine through,
concerning posterior reversible encephalopathy in a patient with elevated blood pressure.

headache, vomiting, cough, and malaise. The patient was
febrile, tachycardic, and tachypneic, with a blood pressure of
213/100 mmHG. She appeared obtunded with dilated and poorly
responsive pupils, right gaze preference, and minimal withdrawal
in all limbs to painful stimuli. Under observation, she suffered
two additional GTCS and was treated with IV lorazepam,
levetiracetam, and fosphenytoin with clinical cessation. Labetalol
was given for hypertension.
The laboratory results were significant for thrombocytopenia
(77 K/µl), hyponatremia (126 mmol/L), elevated creatinine (2.7
mg/dl), blood urea nitrogen (40 mg/dl), and elevated ferritin.
The non-contrast CT of the head and the chest radiograph
were unrevealing. The CSF showed four nucleated cells with
lymphocytic predominance, while gram stain, culture, and herpes

Frontiers in Neurology | www.frontiersin.org

testing were negative. The nasopharyngeal COVID-19 PCR
was positive.
EEG was notable for generalized periodic discharges and
slowing. Brain MRI without gadolinium, due to kidney
dysfunction, showed punctate diffusion positive lesions in the left
precentral sulcus and superior right medial parietal subcortical
regions as well as patchy T2 prolongation in the left frontal,
occipital, and bilateral parietal and cerebellar regions, most
consistent with posterior reversible encephalopathy syndrome
(PRES) (Figure 2).
The patient remained obtunded without seizures on
continuous EEG, with steady improvement of her hyponatremia
and blood pressure. Though PRES was of primary concern, a
5-day course of high-dose IV methylprednisolone was given due
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FIGURE 3 | (A–H) Case 4: 68-year-old, COVID-positive female. (A,B) Hyperfine 0.064-T portable MRI obtained 26 days after admission at the patient’s bedside
showing focal T2 and FLAIR hyperintensities (red arrows). (C–H) 3-T MRI obtained 39 days after admission. (C) Axial T2 and (D) axial FLAIR hyperintensities (red
arrows): left subinsular cortex, lentiform nuclei, thalami, and left temporal lobe. (E,F) Axial FLAIR, (G) axial ADC, (H) axial DWI, T2, FLAIR, and DWI hyperintensities
(red arrows): bilateral olfactory tracts, medial temporal lobes including hippocampal tails, caudate heads, fornices and posterior commissural fibers, right posterior
lateral temporal lobe without restricted diffusion.

areas of T2 and FLAIR hyperintensity in the left
thalamus and lentiform nuclei, though technically limited
(Figure 3).
By day 27, she was extubated but remained confused, with
the psychomotor slowed, and unable to follow commands.
EEG on day 33 revealed unremitting high-amplitude
centrotemporal sharp rhythmic 3–5-Hz activity concerning
non-convulsive status epilepticus (NCSE) (Figure 4). Clinical
improvement was noted on the following day after the
administration of IV lorazepam, levetiracetam, and lacosamide,
with EEG transitioning to moderate background, slowing
with intermittent left temporal sharp waves. The CSF
results on day 36 were normal, including for COVID19 PCR. A follow-up 3-T contrast-enhanced brain MRI
on day 39 showed T2, FLAIR, and diffusion-weighted
imaging (DWI) hyperintensity without restricted diffusion
along the bilateral olfactory tracts, caudate heads, posterior
commissural fibers of the fornices, hippocampal tails, and
right temporal lobe (Figure 3). By day 49, the patient was
discharged to rehabilitation, alert and capable of conversation,
though with moderate persistent cognitive and bilateral
proximal weakness.

to consideration of inflammation-mediated seizures associated
with COVID-19. The respiratory function was stabilized, and
mentation improved by day 10. On day 21, she was discharged
home at clinical baseline.

Case 4
A 68-year-old woman presented for diarrhea, fever, malaise,
cough, and shortness of breath and found to be positive
for COVID-19 3 days prior. She was febrile, tachycardic,
tachypneic, and hypoxemic upon arrival. The chest X-ray
showed bilateral lung infiltrates for which she was treated with
azithromycin, ceftriaxone, and hydroxychloroquine. The patient
decompensated, requiring intubation due to acute respiratory
distress syndrome, and was given methylprednisolone
and anakinra.
At 2 weeks into her course, the patient remained
obtunded off of sedation. The head CT obtained on
days 16 and 25 after admission demonstrated decreased
attenuation in the left subinsular cortex and the thalamic
region. EEG on day 17 showed severe generalized
slowing. On day 26, portable 0.06-T MRI (Hyperfine)
of the brain without contrast was performed, showing
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FIGURE 4 | (A,B) Case 4. Video EEG results. (A) Day 1 showing the high-amplitude rhythmic sharply contoured; intermixed 3- and 6-Hz activity concerning
non-convulsive status epilepticus. (B) Day 2 with resolution of rhythmic slowing after the administration of lorazepam and levetiracetam, corresponding with improved
mentation. Low-frequency filter, 1 Hz; high-frequency filter, 70 Hz; sensitivity, 7 µV/mm; timebase, 30 mm/s.

In summary, the first case presented with seizures during
the early acute phase of infection, with elevated inflammatory
markers, and FLAIR changes in the temporal region on
MRI indicative of focal inflammation (Figure 1A). Lumbar
puncture did not reveal an evidence for encephalitis. In addition
to antiseizure medications, the patient responded well to
immunotherapy, with good neurological outcome, supporting
a hypothesis of excessive innate immune activation. In case 2,
the seizures resulted from acute CVT in the left transverse and
sigmoid sinus, resulting in a left temporal lobe venous infarct
(Figures 1B,D), highlighting a coagulopathic state associated
with COVID-19. The seizures observed in case 3 manifested in
the setting of a patient with elevated blood pressure and endstage kidney disease with PRES, raising concern for COVID-19
effects on endothelial cell function and vascular permeability.

Summaries of the pertinent clinical details of each case are
presented in Table 1.

DISCUSSION
The cases above describe four scenarios of seizures occurring
in association with COVID-19, illustrating the remarkable
variety of neurological complications accompanying this disease.
Seizures in this report may occur by differing mechanisms,
including in the context of inflammatory changes in the brain
as demonstrated by neuroimaging or vascular abnormalities
related to the effects of SARS-CoV-2 on hypercoagulability and
endothelial cell dysfunction.
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of patients with COVID-19 and EEG are published to date,
with the patients in these studies only undergoing routine
duration or reduced montage EEG recording, for the reasons
discussed above, and less frequently continuous EEG monitoring.
Several authors observed sporadic epileptiform abnormalities
and periodic patterns of concern, including generalized periodic
discharges, along with more expected patterns of generalized
slowing (22–26). Due to centers taking precautions to avoid
transmission risk by reducing staffing and utilization of EEG,
as well as obtaining imaging, cases of electrographic seizures
and NCSE may be less likely to be diagnosed and adequately
imaged. While the safety and risks of infection must be weighed
carefully, patients may potentially benefit from the use of EEG
and neuroimaging to recognize potentially treatable seizures.
The speculative mechanisms responsible for the neurological
manifestations of SARS-CoV-2 are grouped broadly into direct
viral invasion and indirect effects via systemic inflammation,
coagulopathic states, endotheliopathy, and homeostatic
disruptions, including metabolic derangements due to hypoxia
and organ failure.
Given the genetic semblance between SARS-CoV and SARSCoV-2 and the shared manner of cellular entry via receptors
for angiotensin-converting enzyme II (ACE2), neurotropism
may be similar (27). Previous studies have demonstrated SARSCoV antigens and RNA within human neurons, supporting a
hypothesis of neuroinvasion in SARS-CoV-2 (28). One proposed
route of direct cell invasion involves receptors for ACE2, found
on the surface of glia and endothelial cells, allowing for distinct
ports of CNS entry (29, 30). CNS penetration may involve transaxonal transport along adjacent glia or hematogenous spread.
Invasion via cells expressing ACE2 in the olfactory tract may lead
to encephalitis associated with seizures and MRI signal changes
indicative of edema and inflammation (3).
The upregulation of proinflammatory cytokines may also
play a role in para-infectious immune-mediated neurological
complications, such as demyelinating disease, acute necrotizing
encephalopathy, or Guillain–Barre syndrome in COVID19 (31–36). Endothelial dysfunction and disruption of the
integrity of the blood–brain barrier may result in cerebral
antigen exposure and increased susceptibility to abnormal
adaptive immunity. Similar neuroimmunological manifestations
are reported with other coronaviruses, and seizures have
been reported in this context (HCoV-OC43, SARS CoV, and
MERS) (14, 30). These neurological presentations highlight
the need for brain imaging in encephalopathic patients with
COVID-19, particularly those with focal neurological deficits or
seizures, which may reflect aberrant and excessive autoimmune
phenomena. The neuroimaging findings in COVID-19 are
extremely heterogenous and may vary based on the severity
of infection (37). Immunotherapy, such as corticosteroids,
targeted molecular therapies such as monoclonal antibodies,
IV immunoglobulins, or convalescent plasma for patients with
these manifestations may be potentially beneficial, though
more systematic research is required (36, 38–40). During their
course of treatment early on in the New York area pandemic,
three patients in our series received methylprednisolone,
two received hydroxychloroquine, one received tocilizumab,

This patient demonstrated classic findings of increased T2,
DWI, and FLAIR hyperintensity without restricted diffusion
in the setting of elevated blood pressure (Figures 2A–F) and
with a few punctate foci of restricted diffusion and ischemic
change. The association of PRES as a neurologic complication
of COVID-19 has been recently documented in the literature
(15–18). The final patient was determined to have seizures
later in her course, along with persistent altered mentation
and radiographic findings suggestive of inflammatory changes
and concern for immune-mediated necrotizing encephalopathy.
Early portable magnetic resonance imaging using a Hyperfine
MRI at the bedside, as the patient was too unstable to come
down to the scanner (Figures 3A,B), demonstrated thalamic
T2 and FLAIR hyperintensity, with follow-up conventional
magnetic resonance imaging 2 weeks later showing bilateral
hippocampal, forniceal, sub-insular, and orbitofrontal T2 and
FLAIR abnormalities. Initiating antiseizure medications led to
significant electrographic improvements and eventual delayed
clinical improvement.
A few recent case reports are published in the literature
describing acute symptomatic repetitive seizures in the setting
of COVID-19. In an early report, the patient had positive CSF
COVID-19 PCR and mesial temporal and lateral ventricular
signal hyperintensities on MRI indicative of encephalitis
(3). Additional rare cases may present with lymphocytic
pleocytosis (19).
De novo focal seizures including status epilepticus in the
absence of other medical comorbidities, neuroimaging, or
lumbar puncture abnormalities are also described (7, 9–12, 20).
New-onset seizures are reported in medically complex elderly
patients with COVID-19; however, these were in the setting
of multiorgan failure, metabolic derangements, and, in certain
patients, superimposed sepsis or hypotension as complicating
factors, and unfortunately, MRI or lumbar puncture results
were often unavailable (4, 7, 8). Seizure exacerbation and status
epilepticus may also be exacerbated in patients with preexisting
epilepsy and focal lesions, where COVID-19 infection may have
lowered the seizure threshold (5, 21).
In a series of 214 consecutive patients with COVID-19 from
China, only one individual experienced a convulsion, although
16 additional patients were reported with unspecified impaired
consciousness (1). An additional retrospective multicenter study
of 304 consecutive patients with COVID-19 reported only two
cases of seizure-like events (2). One patient presented with
facial deviation and acute anxiety, while the other experienced
myoclonus with electrolyte imbalance. Eight additional patients
were described as encephalopathic or comatose. Notably, in both
publications, EEG was not performed due to concerns regarding
infection control.
Although clinical seizures are infrequently encountered with
COVID-19, NCSE may still need to be excluded by EEG
in patients with unexplained altered mentation. Investigators
recognize encephalopathy as a common occurrence among
severely ill patients with COVID-19; however, concurrent EEG
data are often unavailable, and further research is required
to understand the true incidence of electrographic seizures in
patients with SARS-CoV-2 infection. Relatively small cohorts
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TABLE 1 | Case summaries.
Seizure
semiology

Intubated

Serum inflammatory
markers

CSF results

EEG findings

Radiological findings

Possible
mechanism of
neuronal injury

CASE # 1

Fever, cough,
vomiting, malaise,
fever, tachycardia

Global aphasia,
bilateral babinski
signs

GTCS

Yes

ESR = 9;
CRP = 32.6;
D-dimer = 279;
Fibrinogen = 352;
Ferritin= 357.4;
Procalcitonin = 1.23

WBCs = 5/uL;
Protein = 125 mg/dL;
Glucose = 117 mg/dL;
Gram Stain, culture,
and HSV PCR
negative;
COVID-19 PCR
unavailable

Severe generalized
slowing

MRI brain: T2
hyperintensities in the
medial temporal lobes

Viral invasion vs.
secondary
inflammation

CASE # 2

Fever, cough,
dyspnea,
headache,
tachycardia

Encephalopathy,
right hemiparesis

FBTCS

No

ESR = 30;
CRP = 111.7;
D-dimer = 2,876;
Fibrinogen = N/A
Ferritin= 10.4;
Procalcitonin = 0.06

N/A

Asynchronous
slowing and left
sided attenuation

CT head: edema, mass
effect and subcortical
hemorrhages in the left
temporal and parietal lobes.
CTV: left sigmoid and
transverse cortical venous
thrombosis

CVT

CASE # 3

Headache,
vomiting, cough,
malaise,
hypertension

Encephalopathy

FBTCS

No

ESR = 22;
CRP = < 0.1;
D-dimer = < 150;
Fibrinogen = 588;
Ferritin= 3,647;
Procalcitonin = 0.45

WBCs = 4/uL;
Protein = 43 mg/dL;
Gram Stain, culture,
and HSV PCR
negative;
COVID-19 PCR
unavailable

GPDs

MRI brain: multiple diffusion
positive lesions in the left
precentral sulcus and right
medial parietal regions;
patchy T2 prolongation in
the left frontal, occipital, and
bilateral parietal and
cerebellar regions

PRES

CASE # 4

Fever, diarrhea,
malaise, cough,
dyspnea

Coma, subsequent
prolonged
encephalopathy

NCSE

Yes

ESR = 77;
CRP = 22.8;
D-dimer = 1,137;
Fibrinogen = 747;
Ferritin= 22.8;
Procalcitonin = 0.29

WBCs = 1/uL;
Protein = 30 mg/dL;
Glucose = 73 mg/dL;
Gram Stain, culture,
and HSV PCR
negative;
COVID-19 PCR
unavailable

High amplitude
rhythmic
frontotemporal
theta, intermixed
left temporal sharp
waves

MRI Brain = T2, FLAIR and
DWI hyperintensity without
restricted diffusion along the
bilateral olfactory tracts,
caudate heads, fornices,
hippocampi and right
temporal lobe

Secondary
inflammation

November 2020 | Volume 11 | Article 576329

Key: GTCS, Generalized tonic-clonic seizures; GPDs, Generalized periodic discharges; FBTCS, Focal to bilateral tonic-clonic seizures; NCSE, Non-convulsive status epilepticus; PRES, Posterior reversible encephalopathy syndrome;
MRI, Magnetic resonance imaging; ESR, Erythrocyte sedimentation rate; CRP, C-Reactive protein; WBCs, White blood cells; HSV, Herpes simplex virus; PCR, Polymerase chain reaction; COVID-19, SARS-CoV-2; CVT, Cortical venous
thrombosis; CT, Computed tomography; N/A, Not available. Normal laboratory values: ESR = 4–25 mm/h; CRP < 5 mg/L; D-dimer < 230 ng/mL; Fibrinogen = 300–500 mg/dL; Ferritin = 15–150 ng/mL; Procalcitonin = 0.02–0.1 ng/mL;
CSF Protein = 15–40 mg/dL; CSF Glucose = 40–70 mg/dL; CSF WBCs = 0–5 cell/uL.
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and one was administered anakinra. The treatments for
COVID-19 remain highly variable at this time, and therapies
specifically for neurological complications lack consensus. While
potentially helpful for cytokine storming, data have subsequently
called into question the early recommendations to utilize
hydroxychloroquine in hospitalized COVID-19 patients due to
safety concerns (36). While corticosteroids have significant antiinflammatory effects, caution is likewise advised to avoid the
potential delay of viral clearance or other systemic complications,
and timing and dosing of steroids may need to be considered
carefully on a case-by-case basis for more severe cases of
neuroinflammation (41). Research continues in support of drugs
targeting cytokines via the IL-6 receptor, such as tocilizumab, and
IL-1 receptor, such as anakinra (36).
Endothelial dysfunction may contribute to vascular
events such as stroke (35). Viral cellular invasion via
ACE2 expressed on the surface of glia, endothelial cells,
myocardium, and arterial smooth muscle may predispose
patients to thromboinflammation (42). Increases in systemic
proinflammatory cytokines observed in COVID-19 such as IL-6,
IL-10, and TNF-α are associated with hypercoagulability and
microthrombi (43, 44). Elevated D-dimer levels are associated
with thrombus formation and more severe infection and
mortality (42). In one study, 6% of patients with COVID-19 were
found to have acute strokes, theoretically predisposing them to
a higher incidence of seizures (1). Nearly 3% of non-COVID-19
adults with ischemic stroke suffer early seizures, while the rates
of seizures in CVT are as high as 34% (45, 46). CVT, as described
in case 2, in COVID-19 has been reported, and given seizures
as a common presenting feature, one should remain vigilant for
this entity in the appropriate clinical context (47).
PRES in the setting of COVID-19 may similarly involve
elevated cytokines due to systemic hyperinflammation,
leading to endothelial activation and increased cerebrovascular
permeability and edema. In the patient presented, underlying
hypertension and renal disease may have been predisposing
factors exacerbated by COVID-19, with additional cases of PRES
in COVID-19 also reported (15, 16, 18, 48).
Acute seizures may also occur as a result of other
systemic complications of COVID-19 resulting from hypoxia
and inflammation, including multiorgan failure and associated
metabolic disorders such as uremia, electrolyte abnormalities,
and potential drug toxicity (14).
Seizures are a serious neurological manifestation of COVID19. Their occurrence may be a concerning indicator of direct

viral CNS involvement, autoimmune-mediated inflammation of
the brain, neurovascular compromise, or cerebral autoregulatory
abnormalities for which clinicians may need greater awareness of
as potentially grave complications of SARS-CoV-2. Appropriate
early diagnosis and treatment, with interventions such as
antiseizure medications, immunotherapy, or modulation of
blood pressure, may improve the outcome in these cases.
Continued research is required to understand the true prevalence
of electrographic seizures in a COVID-19-related neurological
illness in a larger case series and to correlate those findings with
radiographic abnormalities and effects on clinical outcome.
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